5 assets in Astrocytoma (Excluding Glioblastoma)

Therapeutic assets addressing Astrocytoma (Excluding Glioblastoma), rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
gi-102 Astrocytoma (Excluding Glioblastoma)	Mayo Clinic	P2	CCC (53)
Niraparib Astrocytoma (Excluding Glioblastoma)	University of Oklahoma	P2	CCC (53)
Pembrolizumab Astrocytoma (Excluding Glioblastoma)	Mayo Clinic	P2	CCC (53)
Eras-801 Astrocytoma (Excluding Glioblastoma)	Jonsson Comprehensive Cancer Center	P1	CC (43)
Fludeoxyglucose Astrocytoma (Excluding Glioblastoma)	Jonsson Comprehensive Cancer Center	P1	CC (43)